Advising people all over the world on health issues and enabling them to lead healthier lives was the driving force behind our company founder - this is how the Swabian success story began.
Our biofactors set standards in over 35 countries. In every country where we do business we want to meet the highest expectations of its market. Therefore we have a specific product portfolio in each country.
Wörwag Pharma is taking over contract manufacturer Mauermann-Arzneimittel KG with immediate effect. The Böblingen-based pharmaceutical specialist is thus investing in its own production capacities.
Böblingen, March 16, 2023 – The Böblingen-based pharmaceutical and family-owned company Wörwag Pharma closed the 2022 financial year with an increase in sales of almost eight percent compared to the previous year. Further growth is planned for 2023 in conjunction with a wide range of investments.
An international expert panel published recommendations for diagnosis and management of diabetic neuropathy. Wörwag Pharma provides information on the current consensus recommendations for health care professionals.
